Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive
- ByFXEmpire-
By Divya Chowdhury and Lisa Pauline Mattackal
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| NASDAQ | USD | Real-time | ||
| OTC Markets | USD | Delayed | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
By Divya Chowdhury and Lisa Pauline Mattackal
AstraZeneca (GB:AZN) announced that its COVID-19 vaccine Vaxzevria has been granted approval for use as a third-dose booster shot in adults in the European Union (EU). Approved by...
Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the...
Harbour BioMed out-licensed global rights for a pre-clinical bispecific candidate to AstraZeneca in a $350 million agreement. Harbour BioMed will receive $25 million upfront and as...
The year 2020 has not been kind to the oil industry. Brent crude, the international benchmark, started the year around $60. By late April, it was below $20. When various lockdowns...
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 4.85 | 4.89 | 4.84 | +0.010 | +0.21% | 271.00K | Philippines | |||
| 76.70 | 76.70 | 76.50 | 0.00 | 0.00% | 1.22K | Philippines | |||
| 95.60 | 96.45 | 94.25 | -0.34 | -0.35% | 1.27M | Philippines | |||
| 3.24 | 3.25 | 3.20 | +0.010 | +0.31% | 223.00K | Philippines | |||
| 4.57 | 4.66 | 4.53 | -0.0900 | -1.93% | 5.54M | Philippines | |||
| 7.24 | 7.30 | 7.09 | -0.030 | -0.41% | 160.80K | Philippines | |||
| 12.98 | 13.00 | 12.96 | +0.060 | +0.46% | 264.20K | Philippines | |||
| 104.70 | 104.80 | 104.00 | -0.20 | -0.19% | 170.00K | Philippines | |||
| 51.35 | 51.90 | 50.80 | -0.850 | -1.63% | 2.75M | Philippines | |||
| 0.415 | 0.42 | 0.41 | +0.005 | +1.22% | 4.69M | Philippines | |||
| 53.80 | 53.80 | 52.50 | +1.05 | +1.99% | 1.64M | Philippines | |||
| 18.44 | 18.50 | 18.40 | +0.040 | +0.22% | 64.80K | Philippines | |||
| 0.42 | 0.43 | 0.42 | -0.005 | -1.18% | 4.31M | Philippines | |||
| 21.30 | 21.45 | 21.10 | -0.350 | -1.62% | 701.60K | Philippines | |||
| 4.42 | 4.43 | 4.33 | +0.070 | +1.61% | 121.00K | Philippines |